Kamada (NASDAQ:KMDA) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Kamada (NASDAQ:KMDA) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.05, FiscalAI reports. The business had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million. Kamada had a net margin of 11.21% and a return on equity of 7.73%.

Here are the key takeaways from Kamada’s conference call:

• Record first-half performance: Revenue rose 13% year over year to $100.2 million, adjusted EBITDA increased 14% to $25.7 million, and net income grew 18% to $13.4 million. Second-quarter revenue and EBITDA also reached company records, with a 26% EBITDA margin.
• Kamada reiterated its 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, noting that first-half results are approximately 50% of the annual midpoint and that it remains comfortable with second-half expectations.
• The company signed a three-year, $50 million normal-source plasma supply agreement, with initial commercial sales expected in the fourth quarter of 2026. Houston and San Antonio facilities are expected to provide roughly $16 million–$20 million of annual capacity, while specialty plasma will support Kamada’s own products.
• Management reported continued demand growth for KEDRAB, VARIZIG, HepaGam B and other commercial products, alongside expansion of its biosimilar distribution business in Israel and the MENA region. Kamada expects its biosimilar portfolio to generate $15 million–$20 million in annual sales within several years.
• CFO Chaime Orlev will leave the company at the end of 2026 after nine years, and Kamada has begun searching for a successor, creating a near-term executive-transition risk.

Kamada Price Performance

Shares of Kamada stock traded down $0.18 during trading on Wednesday, hitting $6.91. The stock had a trading volume of 313,355 shares, compared to its average volume of 60,486. Kamada has a 12 month low of $6.50 and a 12 month high of $9.35. The firm’s fifty day simple moving average is $7.23 and its 200-day simple moving average is $7.98. The stock has a market cap of $397.39 million, a PE ratio of 19.74, a PEG ratio of 0.65 and a beta of 0.86.

Analysts Set New Price Targets

KMDA has been the topic of a number of analyst reports. Wall Street Zen cut shares of Kamada from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. William Blair set a $15.00 price objective on shares of Kamada in a research report on Tuesday, July 21st. Weiss Ratings lowered shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, June 25th. Finally, Benchmark reaffirmed a “buy” rating on shares of Kamada in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $13.00.

Institutional Investors Weigh In On Kamada

Several hedge funds and other institutional investors have recently modified their holdings of the business. Aristides Capital LLC lifted its position in shares of Kamada by 4.5% in the 4th quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 1,430 shares during the period. NewEdge Advisors LLC increased its holdings in shares of Kamada by 4.2% in the 3rd quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock valued at $366,000 after acquiring an additional 2,125 shares during the period. Barclays PLC increased its holdings in shares of Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 3,862 shares during the period. Two Sigma Investments LP raised its position in shares of Kamada by 4.3% in the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock worth $761,000 after acquiring an additional 4,504 shares in the last quarter. Finally, Man Group plc raised its position in shares of Kamada by 19.9% in the 4th quarter. Man Group plc now owns 34,294 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 5,684 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.